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The cooperative North !4candi~vian Emlapril Survival 
Study (CONSENSUS) (1) aad Studies of Left Ventriadar 
Dystktion (SOLVD) treatment (2) trials established the 
etktiveaess ofan&ensin-con~ enzyme inhibitors to
improve survival in patients with symptomatic left ventric- 
ular dysfunction. The CONSENSUS trial (1) showed im- 
proved survival inments in New York Heart Association 
funWnalchusIVandtheSOLVDheatmenttrial(2)in 
patients in functional class I to III. The V-HeFf II (3) trial 
conikmed the eEectiveness of aq$otensin-converting n- 
zyme iahibitors in patients with symptomatic left ventricular 
dysfunctionaads~tedthattheseagentswerew~ 
by mechanisms other than vasodikii. Hydmlazine and 
isosorbidedinitmtearesuperiortoplaceboandpra&nin 
improving survival (4). but were not as ektive as enalapril 
in imaeoviag survival inV-Hem II (3). However, they were 
superior toenahqril n imprming left ventricular ejection 
fractionandexerciseperformana, sq$@n#thatthiscom- 
binatknofanar&ialandavenousd&orprovidesbetter 
vaaodiMm than did enalapr& On the basis ofthese studies, 
there is ovenvhelmiag evidence fix the e&ctiveness of . 
aagaMA-convert@ enzyme inhibitors in patients with 
symptomatic left ventriular dysfanction. The SOLVD pro- 
ventiontrial(5)wasanattempttoextendtheseobservati~ 
to determine whether o not aqgiotensin~v~ enzyme 
inhibitors were eifective in patients with left ventricular 
dysfunction but without symptoms ~@riag conventional 
therapy for heart failure. 
In the SOLVD study (a), patients with a left ventricular 
ejection fraction ~35% were stratified into those with symp- 
tomatic and asymptomatic left ventricular dysfunction. After 
stmtkation, patients wete given a test dose of eulapril, 
2.5 mg twice daily. Ifthe test dose was tolerated, the patients 
wee wikhawn from emdapril therapy and observed dmiu 
their baseline therapy to enskmz that they were in stable 
condition. If their condition was stable and i they were 
shown to comply with theii blinded medication, they were 
stratiMtoeitheratreatmentarm(ifthey were symptomatic 
and required therapy for heart failure) or to a prevention arm 
(ifthey were as~ptomatic and id not require such therapy) 
andthenra&muedtotreatmentwithenalapAorplacebo 
inkeasingdosesfiom2.5~to lOmgtwicedaily.Ak 
randomization, patients were followed up for approximately 
3 years to determine the ekt ofemdapril on survival nd 
hospitalkation f r heart f&ilure. 
SOLVD Prevention Trial 
The characteristics of the patients in the SOLVD preven- 
tionarmQareahowninTablel.Themeanegcofthese 
patientswasS9yearsand89%weremen.Themeanleft 
v ntricular ejection fraction was 28%. More than 80% of the 
patiePtshadischemicheartdi~assthe~dtheirleft 
ventricular dysfunction. Most had a history of myocardial 
inkction. Sixty-seven percent were in functional class 1and 
33% in class II. The physicians caring kr the many patients 
infuactkdchusIIatthetimeofrandomizationdidaot 
believethatthesepa&ntsrequiredconventio~Itherapyfm 
heart Khue such as diuretic agents, diixin or m. 
However, it should be pointed out that hese patients could 
havelxentakingdigoxinbecauseofatrialiMUatioa,di- 
uretic agents because ofhypertension or V-J such 
as nitroglycerin for angina pectok. Approximately 34% of 
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T&b 1. studies of Len vclttrictllar Dydlttctloll @oLvD) 
Revention lkiak Basehe characteristics of the 4,228 
shldy Patients 
AgeO(mean) 59.1 
LVBF 0 28.3 
Male lmtiatts (461 88.6 
Is&emic etiology of ventric~~lnr dys!imctiaa (%) 83.2 
NYHA &II!? (no) 
I 66.7 
II 33.1 
Ill 0.1 
Iv 0 
CWT-WiODi%I 33.8 
LVEF=I&ventriadarejmim6nction;NyHAelsss=NcwYork 
Hew Assaciiw functional c ass. 
the patients in the trial had active atgina pectoris. Most 
patients (75%) were not takin8 either digitalis or diuretic 
agents for any reason. The prevalence of angina pectotis n
patients in the SOLVD prevention trial is of importance 
because in most previous trials of heart failure and left 
ventriculardysfunctionthatusedexercise~asan 
end point, patients were excluded if they terminakd their 
exercisebecauseofanginapecuuis. 
A SOLVD substudy ofq eurohormones at baseline (7) 
showed that patients in the prevention arm had a s@i6cant 
elevation fplasma noteph@rine compamd with that level 
in age- and gender-matched ontrol subjects. However, this 
level was signikantly ess than that seen in putients with 
symptomatic leftventricular dyslktion entered into the 
SOLVD treatment trial (2). There was also an intermediate 
elevation f plasma atrial natriuretic factor in the prevention 
trial. Plasma renin activity was only slightly but significantly 
elevated compmed with the level in age- and gender- 
matched control su@cts. The sltght increa* seen in these 
patients in the prevention arm could be almost entirely 
explained by the use of diuretic agents, which activate he 
re+a$otensin system. Although activation fthe reniu 
m system of patients with sympton& left ven- 
tricular dystimctk entered into the treatment trial (2) was 
expectedandptnvidedtherationalefwtheuseofan 
a@&nsin4onvertin8 enxyme inhibitor, the tinding ofonly 
minimalelevationoftzninactivityintheSCLVDprevention 
trial(5)didnotprovidesupportforthehypothesisthatan 
. . ~v~enxymeinhibitorwouldbeelTective 
in these putients. However, previous data had suggested hat 
inpatientswithmildheartfaihue,eventhoughtherenin- 
angiotensin system was not markedly elevated at rest, 
plasmareninactivityincreasessignificantlydurhlgstrenuous 
exercise (8), thus provid& a rationale for the use and 
efkctiveness ofau a@tenskumvert& enzyme inhibitor 
in this group. Alternatively, one nl@ht postulam that an 
~~enxymei&bitormightbeeiktive 
inpatkntswithoutekvatedplasmareninactivityandthat 
themajoractionofanaqiotensin-convertingenxymeinhib- 
itor is on tissue (9) rather than on plasma ngiotensia- 
Table2 sttldicsofLeffventrieular~@~~~) 
RCVClltiOttTriel:E$iectd~OttMorbidity~MortalTty 
z 
PYb 
DcvcbPmeatofhrtYh! 37 < O.ODl 
Hmpitalizadion fix heart tkilure 36 < 0.601 
Total momhty 8 NS . 
-mor$lity 14 NS 
converting enxyme activity in the myocardium, brain, 
kidney or vascuhu wall, which might be activated inde_ 
pendently of &uua levels. 
The results of the SOLVD prevention trial (5) show a 
si@icantreductioninthedevelopmentofheartfuilme, 
hospitalii for heart fail- and the need for medical 
therapyforheartfail~(Table2).Incontmsttothetreat- 
mentarmofSOLVD(2),however,therewasnosignikm 
decreaseinthetotalmortalitymte.Tkewasatrend 
towardareductioninthecardiovascularmortalityrate,but 
this did not reach prude&d statistical s@&ance. One 
explanationf&thefail~ofenalapriltosi@kntlyreduce 
themortalityrateinthistrialdespitethemarkedredu&nin 
thedevelopmentofheartfaihueisthatbytheendofthe 
folknv-up eriod, Ho% of the patients lal&mkd to 
placebowerebeingtreatedwithopenlabel~ 
converting enzyme inhiiitors because of the development of 
symptomsofheartfail~,therebymakingitdi6tadttoshow 
asigniknil~ene6tofe&prilandadi&rencebetweenthe 
enalaprilandplacebosrmsonanintenttotreatbasis. 
Becausetherewasnobene6tofenalaprhiureigaudto 
survival inthe nu@rity of patients i  theSOLVD prevention 
trial(5)whodidnotdevelopsevereheart&il~rqubing 
hospitaktion, it can be argued that it might be best o 
withhold~vertingenxymeinhibitotxuntilthe 
patient becomes syn@omak. It can, however, be posttk 
latedthattheSOLVDprvventioutrial(!I)mukesWWthe 
etktivenessofenalaprilonsurvival.First,therewasaclear 
trendtowardareductionincrrdioveseularnuutGty,al- 
though it was not statistically signikmt. Second, as ahuady 
mentioned,manyofthepatuuus~toplacebowho 
didnotrequirehospitaWhmforheartfaitureweretreated 
withopenlabel~~vertfngenxymeinbibitors 
becauseOfSymptomsOfheartfsiluredtheredwe~ 
protecMfiomdevelopingmanifestheartfaihuesndbdqg 
hospitalixed.OncethepatientwithlefIventkuhufunction 
becomessympummkthereis,aspoiutedoutintheSOLVD 
ueatmenttlial(2)andasseeninpatientsintheSOLVD 
prev ti ntrial(!5)whowerehoqMxedfwheart~,a 
benefitofenahtprilinngatdtoovemllmortaW.Ifforno 
otherreasonthantoavoidtheemotkaltraumaand~~ 
hospiukttionforheartfbihrre,itwotddseemprudent~ 
treatpatiemswithasymptomatickftventricuhudysfunct~ 
~~angiotensinconvertiseuxymei&ibitor.Eaelapril 
~r sultedinareductionofnewonsetmy~~ 
tion and hospitakatkm fw unstable an&ina (10). The risk/ 
16oA 
ti&APY 
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edaprilinptmdngthedeve~opmentofheart~ot 
thecombinedendpointofdeathorhospi-forheart 
&Pilure~~tOoertainSubsetSdpatieatS,the 
SOLVDinWMi@orsexaminedthe~denaEapril~ 
several~vatiablesinciudingserumsodium, 
CtidOgydVClltricular~C~,~~andleff 
ventricular ejeCtion fiwticm (5). ltlere was no Sigdkmt 
titemctionofena@ilinregardtose~msodiutnor 
etio@ty.However,therewasa&@canthWactum 
elm@uilwithhusehnenaormmmuseandh!ttven~cu: 
qjection&tion.kiapriIhadas@Wantlygreatere&ct 
onsurvivalandthecoinhinedendpointofsurvivalor 
hospitaktiontbrheartiWreinpatientsbcitgttruatedat 
haselk with va&ikus (mainly nittuglycerin because of
concmrellt an&a pecuuis) than on those patients without 
baselineva&ikuuse.Therewasalsoasip@cantly 
greuter~ofena@rilonthecombkdendpointofdeath 
or m for heart &rilure in patients in the lowest 
tertikdleftv~ejection~.Fatientsinthis 
~hadthegreatestbeneiltfromemdapril.Theeikctof 
enal@wasalsoanalyxedinregatdtocertainposthoc 
&elm&d variables that, although not prespecikl i l the 
protocol, were dellned before unblindii of the data. These 
variables inch&d age, gender, functional class, presence of 
anginapectoGsatbwelineandbaseKneuseofdigWs, 
dimeticr4@nt!J,calcium~biockinuagantsoranti- 
plateietagents.l%erewerenosign&anthuemc&sof 
em@riJinregardtoibnctionalclass,age,genderorany 
wuiableexceptthebasdiaeuseofantiplatdetagents.Enal- 
apihada8i8dkdyks8er~tmmortelityinpatie~ 
rccei~antiplateletagentsatbnselinethanonpatientsnot 
rcccivip8 antiplatelet agents. However, there was no signif- 
icauMeractMnregardtothecombkdendpointofdeath 
orhos~llforhemtfailure.Itsholddkpointcdout 
thatthiswasaposthoc su@roupandthat whcnoneanalyxes 
multiple sukroups, one or more may appear statisticany 
sknikllt. The h@iCatiOn OfthiS finding, ifany, must await 
~fromotherlargescalerandomixedtrialsofangiotensin- 
converting enzyme inhiitors. 
. 
-f=TbeFapy 
The suits of the SOLVD prevention hial (5) extend the 
illdktions for angiotensin-convertin# nym inhibitors to
Patients with asymptom& left ventricuk dysfunction. 
Thexeisahighlysisnificantandmurkedreductioninthe 
development of heart failure and hospitalixation f r heart 
failure. The SOLVD substudy b Pouleur et al. (1 I) suggests 
that e&april prevents he development of heart failwe by 
prcventinu progressive left ventricular dilation. in patients 
tu&umx& to placebo, there appeared to be progressive left
ventricular dilation in patients with idiop&ic and with 
ischemiccardiomyopathy.Thisdilationoccwredin@ents 
with ischemic cat&myopathy even though they were ran- 
domixedintotheSOLVDtrialatleast1monthatkandat 
ameanof>1yearafterinktion,sug#estingthatventri~ 
ulardilationisprogressiveandnotconihmdtotheearlydays 
and months at?er ifdktiofl. 
Prevention fheart failure in the SOLVD prevention trial 
(5) was due to the use of an angiotensin-converti~ nzyme 
inhibitoras~. Inpatientswithsymptom&left 
ventricular dysfunctk, augiotensin-converting nzyme in- 
hibitors as monotherapy hasnot been the thetupy ofchoice 
&causethcsedrugsarenota8goodasdiuretkagentsin 
causiuu natriure!& (12) and the&ore should be used ill 
coqj~onwithadiuretic~ttoachievemaximalbenefit. 
However, in asymptomatic patients without clinical evi- 
dcnceofBlidovedoad,thapmphylucticuseofanangiotensin 
couverting enxyme inhibii as monotherapy is beneilcial 
(5). Altboush conwmitantuseofadiureticagentmightbe 
advantageous in prevent@ sodium retention, it might also 
predispose to renal dystbnction a d tissue depletion of
pouts&m and megnesium with the risk of ventricular r- 
rhythmiasandsuddencatdiacdeath.Inpatientswithsymp- 
tomatic left ventricuhu dysiimction, progressive h art Gil- 
mu is the dominant cause of death (2), whereas inpxtients 
with asymptomatic dysfu&on, sudden cardiac death is of 
equal importance (5). 
Stimulation f the reniuang&nsin system by diuretic 
drug-induced hypokaiemia could result in growth factor 
release with potential long-term deleterious e@cts on the 
development of a hero4erusis and of ischemic events (10). 
The results of the Survival and Ventricular Enhugcment 
(SAVE) (13) triul demonshating a sign&ant reduction i  
deathandhospitalixationforheartiWuteinpatientsftom3 
to 16daysa&erinktionisfbrthersupportfortheuseof . . 
qm@ns~~nverting enzyme inhibitors in patients with 
asymptomatic left ventricular dyslbnction. The SAVE trial 
(13) included patients who were asymptomatk nd not 
requiriagtherapyforheartf&ilutc,similartothoseinthe 
SOLVD prevention trial (S), as well as patiems who were 
asymptomatic with conventioual therapy for heart bihlre, 
simiiar to those ia the SOLVD treatment trial (2). On 
thebgsisOfthedataintheSAVEtrial(13),awouldap 
pear easonabIe to treat sympumuuk or asymptomadc pa- 
tients with left veutriadar dysfun&n with an angioknsin- 
converting enxyme inhii in the early postWr&n pe 
riod. On the basis of the SOLVD preventiou trial (5), 
patients with asymptomatk leftventricular dysfunction not 
receiving anangiotenskonvertiuu enzyme i&iii before 
hospital discharge after Muction and those detected as 
, 
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having nonischemic cardiomyopathy should be treated with 
an angiotensin-converting enzyme inhibitor when seen as 
outpatients, even several years after infarction or the onset 
of left ventricular dysfunction toprevent the development of 
and hospitabtion for heart failure. 
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